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Background: Verbal autopsy could be more widely used if interpretation by computer algorithm could be
relied on. We assessed how InterVA-4 results compared with clinician review in diagnosing HIV/AIDS-related
deaths over the period of antiretroviral (ART) roll-out.
Design: In the Karonga Prevention Study demographic surveillance site in northern Malawi, all deaths are
followed by verbal autopsy using a semi-structured questionnaire. Cause of death is assigned by two clinicians
with a third as a tie-breaker. The clinician review diagnosis was compared with the InterVA diagnosis using the
same questionnaire data, including all adult deaths from late 2002 to 2012. For both methods data on HIV
status were used. ART was first available in the district from 2005, and within the demographic surveillance
area from 2006.
Results: There were 1,637 adult deaths, with verbal autopsy data for 1,615. Adult mortality and the proportion
of deaths attributable to HIV/AIDS fell dramatically following ART introduction, but for each year the
proportion attributed to HIV/AIDS by InterVA was lower than that attributed by clinician review. This was
partly explained by the handling of TB cases. Using clinician review as the best available ‘gold standard’, for
those aged 1559, the sensitivity of InterVA for HIV/AIDS deaths was 59% and specificity 88%. Grouping
HIV/AIDS/TB sensitivity was 78% and specificity 83%. Sensitivity was lower after widespread ART use.
Conclusions: InterVA underestimates the proportion of deaths due to HIV/AIDS. Accepting that it is
unrealistic to try and differentiate TB and AIDS deaths would improve the estimates. Caution is needed in
interpreting trends in causes of death as ART use may affect the performance of the algorithm.
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O
ver the past 20 years, there have been dramatic
changes in both the levels and causes of mortality
in sub-Saharan Africa. Initial catastrophic rises
in mortality due to HIV have been partially curtailed by
antiretroviral therapy (ART) (1), and deaths due to dis-
eases conventionally associated with more affluent socie-
ties are becoming more prominent (2).
Few countries in sub-Saharan Africa have vital regis-
tration or death certification, so estimation of mortality
rates and distribution of causes of death relies on indirect
methods or on detailed studies in demographic surveil-
lance sites. In these sites, regular population updates
through repeated censuses and/or continuous registration
systems ensure almost complete registration of births and
deaths. Accurate determination of the cause of death is
much more complex. Many deaths will occur without
clinical care, and diagnostic facilities for those who do
reach care are often limited.
Demographic surveillance sites rely on verbal autopsy
to classify major causes of death (3, 4). An informant,
preferably the caregiver during the final illness, is in-
terviewed using a set of standard questions. Information
may be added from health passports if available. A di-
agnosis is made based on clinician review or through
computer algorithms such as InterVA (5). In another
paper in this series, the performance of InterVA-4 based
on responses only (not HIV status unless reported during
the verbal autopsy) was assessed against known HIV
status across six demographic surveillance sites (6). This
showed a high specificity (90%) but could not estimate
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sensitivity as HIV-positive individuals can die from
other causes.
The Karonga Prevention Study, one of those six sites,
has unusually detailed data collection and clinician review
(7). We have previously documented adult mortality rates
and causes of death up to 2009, showing a decline in all-
cause mortality following antiretroviral roll-out and re-
placement of HIV/AIDS by non-communicable disease
as the leading cause of death (2). We now update this
analysis to 2012 and assess the performance of InterVA
against the conclusions reached by the clinicians and
investigate how this varies by age group, sex, time period
(pre- and post-antiretroviral roll-out), and HIV status.
Methods
The demographic surveillance site covers a population of
about 35,000 in the southern part of Karonga District,
northern Malawi. It is predominantly rural, although half
of the population lives within 1 km of a tarmac road. The
main occupation is subsistence farming. HIV was already
present in the area in the early 1980s. The prevalence
peaked in the mid-1990s and is now around 9% in women
and 7% in men (8). The HIV is mainly subtype C (9).
Demographic surveillance started in 2002, with a base-
line house-to-house census which covered the whole
area by 2004 (10). This records detailed data on personal
identifiers, sociodemographic and economic status for
all individuals, and the physical location of all households.
Community-based key informants are responsible for up-
dating information within defined geographical areas that
cover between 30 and 40 households. They report monthly
on births and deaths and collect migration data for annual
reports in their area. Births and deaths are followed-up
immediately by the field staff, and all events are checked
during annual re-censuses.
In 200506, a HIV sero-survey was conducted in
selected clusters of the demographic surveillance area.
Between 2007 and 2011, four annual house-to-house HIV
sero-surveys were completed in the whole demographic
surveillance area. HIV rapid tests were used, with results
available to the participants during the visit (11). The sero-
surveys followed about 6 weeks after re-census in each
area (8). All adults (]15 years old) who were resident
in the demographic surveillance area at the time of the
re-census were visited at home, with up to three repeat
visits if necessary. Consent was sought separately for in-
terviewing and HIV testing. Participants were encouraged
to know their status, but could accept testing and choose
not to know the result, in which case HIV testing was
performed at project headquarters. Interviewers asked
about previous HIV testing, including the timing and
result of the most recent test, and about ART use if the
participant reported that they were HIV positive. HIV-
positive individuals who elected to know their status were
referred for screening for eligibility for ART. HIV results
are also available from linked epidemiological studies
within the area.
Free ART was first available at the Karonga district
hospital in July 2005, in the rural hospital within the
demographic surveillance area in September 2006, and
at further clinics within the area from October 2010. By
mid-2008, ART uptake in the demographic surveillance
area was estimated to be 58% of those eligible (12). Initial
criteria for eligibility were WHO stage 3 or 4 disease
or CD4 of B250 cells/mm3 (after a brief period of B200).
CD4 counts were rarely available so eligibility was usually
assessed clinically. The criteria for eligibility widened to
include those with CD4 up to 350 cells/mm3 in July 2011.
Cause of death
After a death has been reported by a key informant, a
verbal autopsy is conducted as soon as possible, after
allowing a 2-week mourning period. An interviewer with
clinical training visits the deceased’s household, and if
consent is given, fills in a semi-structured verbal autopsy
form (2). This is similar to the 2003 INDEPTH verbal
autopsy tool, which was an adaptation of the contem-
poraneous WHO questionnaire (13). Close relatives of the
deceased, preferably those who were present most of the
time or who nursed the deceased before they died, are
asked an open-ended narrative question about the death,
and then a series of closed questions about specific
symptoms. The completed questionnaire is given to two
independent clinicians (physicians or clinical officers) who
independently assign a cause of death. If the two assigned
causes of death are discordant, a third physician reviewer
assesses all the evidence, including the two previous re-
views, and assigns a cause of death. Information on HIV
status is available to the reviewers if known. Data on ART
use was asked specifically from 2009 and may have been
mentioned by relatives before that. Deaths of individuals
with tuberculosis were assigned as ‘TB’, if they had good
evidence of tuberculosis (TB) and no other symptoms of
AIDS. Otherwise, they were classified as ‘AIDS’ or ‘TB/
AIDS unspecifiable’. Different clinicians have assigned
the cause of death over the long period of study. The two
coding clinicians agreed on cause of death (comparing the
categories ‘not TB/AIDS’, ‘AIDS’, ‘TB’, ‘TB or AIDS’,
‘unspecifiable’) for 82% of deaths (Kappa 0.68). Group-
ing the TB and AIDS categories, the overall agreement
increased to 87%, Kappa 0.76.
For the InterVA analysis, the original data from the ver-
bal autopsy forms were entered according to the InterVA-4
required format. Data were directly extracted from the
questionnaire for 112 of the 190 InterVA-4 input items
which are relevant for adult deaths. The remaining input
items were left as missing. Data were available for all
the key symptoms associated with HIV-related deaths
(e.g. oral candidiasis and wasting), and where possible,
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available data on HIV status, including self-report, were
also included in the InterVA input.
Ethical approval
Ethical approval for the study was obtained from the
National Health Sciences Research Committee of Malawi
and the Ethics Committee of the London School of
Hygiene and Tropical Medicine.
Data analysis
Data from August 2002 to the end of 2012 were included.
The study period was divided into three: pre ART (before
7 July 2005); during ART-rollout up to 2 years after
ART availability within the demographic surveillance area
(7 July 20056 September 2008); and more than 2 years
after the availability of ART locally (after 6 September
2008). Person-time at risk (in years) was used as the
denominator in the calculation of all mortality rates.
Analysis was done using Stata version 13 and the InterVA-
4 Model was run through R Studio (version 1.0) (14).
InterVA-4 requires estimates of the prevalence of HIV and
malaria among deaths in the population; these were set to
be high (1% of all deaths).
Analyses compared the overall mortality rates and the
proportion of deaths attributed to HIV/AIDS as estimated
by InterVA and by clinician review. We used the InterVA
estimations [as in Ref. (6)] but included any additional
available HIV data not already reported during the verbal
autopsy. InterVA calculates the likelihood for each cause
of death for each individual, and these are summed across
the whole population or subgroups. We explored the effect
of including or excluding TB cases with AIDS cases in
both the InterVA and clinician estimates as the symptoms
and signs of TB and AIDS are difficult to distinguish.
Finally, we compared the most likely cause of death for
each individual as assigned by InterVA with that assigned
by clinician review. While clinician review is far from
perfect, it is the best available diagnosis, and was used as a
‘gold standard’ against which to estimate the sensitivity
and specificity of InterVA. The data used by the two
methods was almost the same, except that the clinicians
see the narrative which is not available to InterVA, and
InterVA was given additional data on HIV status (from
self-report and ART use data) that was not necessarily
known to the clinicians unless mentioned in the narrative.
Results
From August 2002 to December 2012, a total of 1,637
deaths of individuals aged 15 years and above were re-
gistered in 155,875 person-years at risk giving a crude
mortality rate of 10.5/1,000 person-years [95% confidence
interval (CI): 10.011.0]. Verbal autopsy questionnaire
data were available for 1,618 (99%). Three had no clinician
review available, leaving 1,615 with information from both
methods.
Table 1 shows age-specific all-cause mortality rates
stratified by ART availability. All cause adult mortality
rates declined from 13.8/1,000 person-years (95% CI:
12.615.1) before ART introduction in the district to 8.5
(95% CI: 7.99.2) once ART provision was widespread, with
the reduction seen in all age groups except the over 60s.
The proportion of deaths attributable to HIV/AIDS in
different time periods according to the different methods
of ascribing cause is shown in Table 2 for those aged 1559
and in Table 3 for those aged 60 and over. HIV status was
known (by test result or report) for 606 deaths, of which
Table 1. Age-specific mortality rates per 1,000 person years (all causes, both sexes) by ART availability
Before ART introduction
(before 7 July 2005)
ART introduction
(7 July 20056 September 2008)
2 years local ART
(after 6 September 2008)
Age
group
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
1519 11 6,277 1.75 (0.973.16) 11 10,117 1.09 (0.601.96) 15 13,822 1.09 (0.651.80)
2024 21 5,702 3.68 (2.405.65) 17 9,212 1.85 (1.152.97) 31 10,626 2.92 (2.054.15)
2529 28 4,568 6.13 (4.238.88) 41 7,676 5.34 (3.937.25) 31 9,754 3.18 (2.244.52)
3034 50 3,373 14.82 (11.2319.56) 72 6,203 11.61 (9.2114.62) 30 8,242 3.64 (2.555.21)
3539 49 2,567 19.09 (14.4325.25) 59 4,283 13.77 (10.6717.78) 45 6,554 6.87 (5.139.20)
4044 50 2,016 24.80 (18.8032.72) 46 3,636 12.65 (9.4816.89) 43 4,650 9.25 (6.8612.47)
4549 33 1,670 19.76 (14.0527.79) 41 2,721 15.07 (11.0920.46) 41 3,903 10.50 (7.7314.27)
5054 21 1,172 17.91 (11.6827.48) 35 2,191 15.98 (11.4722.25) 30 3,013 9.96 (6.9614.24)
5559 28 1,220 22.96 (15.8533.25) 36 1,625 22.15 (15.9830.7) 31 2,359 13.14 (9.2418.68)
60 150 3,451 43.47 (37.0451.01) 239 5,861 40.78 (35.9346.29) 302 7,412 40.75 (36.4045.61)
Overall 441 32,015 13.77 (12.5515.12) 597 53,523 11.15 (10.2912.09) 599 70,334 8.52 (7.869.23)
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272 were HIV positive. One hundred and seventy of these
272 HIV-positive deaths were reported as HIV positive as
part of the verbal autopsy, and 286/334 HIV negatives
were reported as negative.
For those aged 1559, the proportion of deaths due to
HIV/AIDS decreased over time whichever method was
used, but the proportion attributed to HIV/AIDS was
higher when based on clinician review than when using
InterVA. This was partially explained by the way TB was
handled by the two methods. If TB deaths were grouped
with AIDS deaths, there was less discrepancy between the
methods. In those aged 60 and over, the proportion of
deaths attributable to HIV/AIDS was much lower, and
similar in InterVA and clinician review. In this age group,
including TB deaths greatly increased the discrepancy,
with InterVA over-diagnosing TB deaths compared to the
clinician review.
To allow a more detailed examination of the diagnoses
reached by InterVA and clinician review, the most likely
cause determined by InterVA for each individual was
compared with that from the clinician review (Table 4).
This shows the results by age group, and for those aged
1559, by sex, time period, and HIV status. Of the 320
deaths in age group 1559 attributed to HIV/AIDS by
InterVA, clinician review attributed 259 to AIDS or TB/
AIDS, 2 to TB only, 6 to other communicable disease, 40
to non-communicable disease, 1 to external causes, and
12 were indeterminate. Of the 124 attributed to TB by
InterVA, only 18 were attributed to TB alone by clinician
review with 11 attributed to TB/AIDS, 75 to AIDS, 2 to
Table 2. Percentage of deaths attributable to HIV/AIDS using different methods of interpreting the verbal autopsy data in
individuals aged 1559
Percentage of deaths attributed to HIV/AIDS
Calendar
year
Number of
deaths
InterVA (not
including TB)
InterVA
(including TB)
Clinician review (excluding deaths
attributed only to TB)
Clinician review (including
all TB deaths)
2002/2003 96 39.6 56.1 67.7 68.8
2004 135 32.9 49.6 59.3 61.5
2005 120 50.5 60.4 60.8 61.7
2006 124 45.1 56.8 50.8 55.7
2007 99 33.9 50.5 41.4 44.4
2008 95 26.6 39.1 36.8 41.1
2009 69 21.8 31.3 40.6 44.9
2010 49 27.3 33.0 38.8 38.8
2011 69 22.3 32.3 30.4 34.8
2012 80 18.1 33.3 30.0 31.3
Overall 936 33.8 46.8 48.0 50.6
Table 3. Percentage of deaths attributable to HIV/AIDS using different methods of interpreting the verbal autopsy data in
individuals aged 60 and over
Percentage of deaths attributed to HIV/AIDS
Calendar
year
Number of
deaths
InterVA (not
including TB)
InterVA
(including TB)
Clinician review (excluding deaths
attributed only to TB)
Clinician review (including
all TB deaths)
2002/2003 33 9.2 20.3 9.1 12.1
2004 70 4.5 15.2 5.7 8.6
2005 84 7.6 14.4 7.1 9.5
2006 71 7.2 11.6 8.5 8.5
2007 74 7.6 15.6 2.7 4.1
2008 76 3.9 7.9 4.0 6.6
2009 75 1.2 13.8 1.3 1.3
2010 71 0.4 9.3 1.4 2.8
2011 58 1.1 6.1 3.5 6.9
2012 67 0 10.5 1.5 6.0
Overall 679 4.2 12.2 4.3 6.3
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Table 4. Comparison of InterVA to causes of death given through clinician review
Clinician review
Main cause of
death assigned
by InterVA
AIDS
death
only
TB/
AIDS
death
TB
death
only
Other
communicable
Non-
communicable
Maternal/
External Indeterminate Total
Overall
(age
1559)
HIV/AIDS 251 8 2 6 40 1 12 320
TB 75 11 18 2 15 1 2 124
Other 96 2 5 84 129 105 26 447
Indeterminate 6 0 0 3 14 10 12 45
Total 428 21 25 95 198 117 52 936
Age
group
1529 HIV/AIDS 40 3 2 2 10 0 1 58
TB 7 2 2 1 3 0 0 15
Other 14 0 0 21 25 55 5 120
Indeterminate 0 0 0 0 4 2 3 9
Total 61 5 4 24 42 57 9 202
3044 HIV/AIDS 141 4 0 2 20 1 9 177
TB 47 7 9 0 6 1 2 72
Other 49 2 4 36 38 35 13 177
Indeterminate 2 0 0 1 4 5 4 16
Total 239 13 13 39 68 42 28 442
4559 HIV/AIDS 70 1 0 2 10 0 2 85
TB 21 2 7 1 6 0 0 37
Other 33 0 1 27 66 15 8 150
Indeterminate 4 0 0 2 6 3 5 20
Total 128 3 8 32 88 18 15 292
60 and over HIV/AIDS 9 0 0 6 14 0 1 30
TB 7 2 10 3 32 0 2 56
Other 9 1 4 81 365 19 66 545
Indeterminate 1 0 0 5 11 2 29 48
Total 26 3 14 95 422 21 98 679
Sex (age
1559)
Men HIV/AIDS 107 5 0 3 19 0 8 142
TB 37 5 13 1 8 0 1 65
Other 49 1 4 57 63 52 16 242
Indeterminate 4 0 0 1 11 8 11 35
Total 197 11 17 62 101 60 36 484
Women HIV/AIDS 144 3 2 3 21 1 4 178
TB 38 6 5 1 7 1 1 59
Other 47 1 1 27 66 53 10 205
Indeterminate 2 0 0 2 3 2 1 10
Total 231 10 8 33 97 57 16 452
Time
period
Before
ART
introduction
HIV/AIDS 95 4 0 2 5 0 3 109
TB 29 9 2 1 4 0 0 45
(age
1559)
Other 40 2 3 20 28 19 13 125
Indeterminate 2 0 0 0 3 5 1 11
Total 166 15 5 23 40 24 17 290
ART
introduction
HIV/AIDS 115 4 2 2 20 1 4 148
TB 30 0 10 1 4 1 1 47
Other 23 0 1 38 47 34 7 150
Indeterminate 1 0 0 1 4 3 4 13
Total 169 4 13 42 75 39 16 358
2 years
local ART
HIV/AIDS 41 0 0 2 15 0 5 63
TB 16 2 6 0 7 0 1 32
Other 33 0 1 26 54 52 6 172
Indeterminate 3 0 0 2 7 2 7 21
Total 93 2 7 30 83 54 19 288
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other communicable disease, and 15 to non-communicable
disease. By contrast there was poor correlation between
InterVA and clinician diagnoses for the over 60s. Of 30
deaths attributed to HIV/AIDS by InterVA, 9 were attri-
buted to AIDS or TB/AIDS by clinician review, with 6
other communicable diseases and 14 non-communicable
diseases. And of 56 attributed to TB by InterVA, clinician
review attributed 12 to TB or TB/AIDS, 7 to AIDS, 3 to
other communicable disease, and 32 to non-communicable
disease.
Diagnoses reached by InterVA and clinician review
were also compared by HIV status (Table 4). Neither
method assigned HIV/AIDS as the cause if there was
a recent negative HIV test (with one exception) and
neither method automatically assigned HIV/AIDS as the
cause if there was a positive HIV test. The relative under-
reporting of HIV/AIDS deaths by InterVA was more
marked in those known to be HIV positive than HIV
unknown: among those known to be HIV positive, HIV/
AIDS deaths were diagnosed for 47% by InterVA and
80% by clinician review (53 and 84%, respectively, if
on ART). For those with unknown status, HIV/AIDS
deaths were diagnosed for 35% by InterVA and 47% by
clinician review.
The sensitivity and specificity of InterVA compared to
clinician review is shown in Table 5 (excluding those with
undetermined cause of death). Among those aged 1559,
the sensitivity of InterVA for identifying HIV/AIDS
deaths was 59% and the specificity was 88%. Sensitivity
decreased with age and was only 32% in those aged over 60.
Among those aged 1559, the sensitivity was lower in the
last period, after ART use was widely established. Speci-
ficity varied less and was lowest during ART introduction.
Grouping HIV/AIDS and TB together greatly impro-
ved the sensitivity of InterVA in all groups, with little loss
in specificity. In the 1559 age group, the sensitivity
was 78% and the specificity 83% for the combined
definition.
Discussion
In this setting, adult mortality rates have fallen dramati-
cally since ART became widely available. This is mirrored
by the decreasing proportion of deaths attributable to
HIV/AIDS. This decrease is seen with both methods of
classifying the verbal autopsy data  InterVA or clinician
review  but there were differences between them, with the
proportion attributed to HIV/AIDS by InterVA being
lower than that attributed by clinician review in all year
Table 4 (Continued )
Clinician review
Main cause of
death assigned
by InterVA
AIDS
death
only
TB/
AIDS
death
TB
death
only
Other
communicable
Non-
communicable
Maternal/
External Indeterminate Total
Known
HIV
status
(age
1559)
HIV negative HIV/AIDS 1 0 0 2 12 0 0 15
TB 0 0 7 0 9 0 0 16
Other 0 0 0 15 46 49 5 115
Indeterminate 0 0 0 1 5 3 7 16
Total 1 0 7 18 72 52 12 162
HIV positive HIV/AIDS 104 4 1 1 8 0 3 121
TB 37 4 6 0 0 0 2 49
Other 49 1 1 12 9 6 2 80
Indeterminate 4 0 0 0 1 0 0 5
Total 194 9 8 13 18 6 7 255
HIV
unknown
HIV/AIDS 146 4 1 3 20 1 9 184
TB 38 7 5 2 6 1 0 59
Other 47 1 4 57 74 50 19 252
Indeterminate 2 0 0 2 8 7 5 24
Total 233 12 10 64 108 59 33 519
On ART HIV/AIDS 37 2 0 0 3 0 1 43
TB 11 0 2 0 0 0 1 14
Other 16 0 0 4 1 1 0 22
Indeterminate 2 0 0 0 0 0 0 2
Total 66 2 2 4 4 1 2 81
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groups for those aged 1559. The difference between
the two methods was particularly marked in those who
were known to be HIV positive.
Part of the difference in performance in the 1559 age
group is explained by the classification of TB and TB/
AIDS deaths. If all TB deaths were grouped with the AIDS
deaths for both methods the results were much more
similar, although clinician review continued to attribute a
slightly higher proportion to HIV/AIDS/TB in this age
group.
In the over 60s, the proportion of deaths attributed to
HIV/AIDS without TB was low and similar in the two
methods. In this age group, the inclusion of TB deaths
greatly increased the proportion attributed to HIV/AIDS/
TB by InterVA, with much less increase in the clinician
review diagnoses. As shown in Table 4, of the 56 TB cases
diagnosed by InterVA in the over 60s, only 34% (19 cases)
were classified as TB or AIDS by clinician review, and 57%
(32 cases) were thought to be due to non-communicable
disease. By contrast, among those aged 1559 diagnosed
as TB deaths by InterVA, 84% (104/124) were classified as
TB or AIDS, and only 12% (15/124) as non-communicable
disease by clinician review. In Karonga, TB case finding
and diagnosis is good, as TB has been a major focus of
studies for 30 years, so it is likely that it is the InterVA diag-
noses that are more often incorrect. In the over 60s,
although the overall numbers attributed to HIV/AIDS
by the two methods was similar, at an individual level
there was poor correlation so the similarity is probably due
to chance.
The estimates of sensitivity and specificity show that
the sensitivity of InterVA can be greatly improved, with
little loss of specificity, by grouping HIV/AIDS/TB as
one diagnostic category. An analysis in Nairobi com-
paring InterVA with AIDS mortality estimates from
spectrum also found under-estimation by InterVA which
was improved by including deaths classified as TB (15).
A study in Ethiopia using hospital diagnoses and HIV
testing as the comparison group found improved sensitiv-
ity without loss of specificity for InterVA when combining
TB and AIDS (16), and a study in Kenya found that
InterVA tended to over-diagnose TB when compared to
hospital diagnoses (17). A comparison in a demographic
surveillance site in Ethiopia found poor agreement
between InterVA and physician review for both HIV/
AIDS and TB diagnoses (18), and worse agreement in
older adults (19). A large multi-country study also found
relatively poor performance by InterVA compared to
physician review where tertiary hospital cause of death
assignments, with stringent diagnostic criteria, were used
as the gold standard (20, 21), though methodological
questions have been raised about some of the comparisons
in this study (22).
Obviously, clinician review of verbal autopsy data is not
a true gold standard. Even pre-mortem clinical diagnoses
in settings with good clinical facilities are often contra-
dicted by conventional autopsy (3, 23, 24), and reaching
a diagnosis based on a limited amount of reported infor-
mation is much more difficult. What the comparison
does test, however, is how well the computer algorithm
performs compared to two (or in cases of discrepancy,
three) clinicians working in the local environment, with
essentially the same information. The results suggest that
using the InterVA definition of HIV/AIDS alone will
underestimate AIDS death, but that it performs better for
the combined diagnosis of HIV/AIDS/TB, and this
amendment could be recommended in the 1559 age
group. Results in the over 60s appear less reliable. The
apparently lower sensitivity of InterVA for diagnosing
HIV/AIDS/TB after established ART use in the popula-
tion suggests that considerable caution will be needed in
interpreting trends in HIV-related deaths.
Table 5. Sensitivity and specificity of InterVA assignment of HIV/AIDS as the main cause of death compared with clinician
review (excluding indeterminates)
Excluding TB Including TB
Sensitivity Specificity Sensitivity Specificity
Overall (1559 years old) 58.5 88.0 78.0 83.0
Age 1529 65.2 88.4 80.0 86.3
3044 58.0 84.9 79.1 78.4
4559 55.9 91.1 74.8 85.0
60 and over 32.1 96.3 66.7 89.4
Sex (1559 years old) Male 54.9 90.0 75.6 84.7
Female 61.5 85.6 80.2 81.1
Time period (1559 years old) Before ART introduction 55.3 91.7 75.5 84.8
ART introduction 69.2 84.5 87.0 80.4
2 years local ART 44.6 89.6 65.7 84.6
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